跳至主要内容
临床试验/NCT02749734
NCT02749734Unknown1 期

Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases

Southwest Hospital, China1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2015年5月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
发起方
入组人数
15
试验地点
1
主要终点
Number of participants with Treatment-Related Adverse Events [Safety and Tolerability]

研究概览

简要总结

The purpose of this study was to determine the safety and therapeutic effect of sub-retinal transplantation of human embryo stem cell derived retinal pigment epitheliums (hESC-RPE) in patients with macular degeneration diseases, and explore new treatment modalities for macular degeneration diseases (Age-related macular degeneration and Stargardt's macular dystrophy).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aging from 18 to 75 years
  • must have signed informed consent
  • At least one visually impaired eye caused by macular degeneration diseases
  • Can not be effectively treated with conventional therapies
  • Best corrected visual acuity scores between 19 and 73 letter in ETDRs (early treatment diabetic retinopathy ) eye chart , including 19 and 73 (or the equivalent of Snellen eyesight from 20/400 to 20/40)
  • Visual loss caused by macular degeneration diseases

排除标准

  • Eyes with concomitant diseases which will interfere the visual improvement of the study
  • Active intraocular inflammation regardless of the grade of severity
  • Active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, ophthalmia)
  • History of uveitis
  • Severe cataract, glaucoma, retinal blood vessels occlusion, retinal detachment, macular hole, vitreous-macula traction
  • Iris neovascularization
  • Patients who have only one functioning eye, or the best corrected vision of untreated eye scores less than 24 letters in ETDRS chart(corresponding to 20/320 in Snellen chart)
  • History of intraocular surgery
  • Severe systemic diseases: Stroke, coronary heart disease, angina pectoris, renal insufficiency needing dialysis
  • Allergic to sodium fluorescein
  • Uncontrolled hypertension (systolic pressure>140mmHg,or diastolic pressure>90mmHg)
  • Coagulative function disorder
  • System administration of drugs that are toxic to lens, retina, or optic nerve like hydroxychloroquine, phenothiazine, ethambutol, tamoxifen, etc.
  • Involved in other clinical trials of any medicine within 1 month (or within 5 half-life periods)
  • Have maternity plan in 6 months
  • In pregnancy or lactation period.

研究组 & 干预措施

hESC-RPE

Experimental

Subretinal transplantation of Human embryo stem cell derived retinal pigment epitheliums

干预措施: Subretinal transplantation (Procedure)

结局指标

主要结局

Number of participants with Treatment-Related Adverse Events [Safety and Tolerability]

时间窗: up to 12 months

Patients with Treatment-Related Adverse Events caused by local rejection of implanted cells or systemic immunosuppression treatment

次要结局

  • Flash Electroretinogram (FERG)(up to 12 months)
  • Visual Field as examined by Static perimetry(up to 12 months)
  • Number of Early Treatment Diabetic Retinopathy (ETDR ) letters participants can recognize(up to 12 months)
  • Amplitude and Latency of Flash Visual Evoked Potentials (FVEP)(up to 12 months)
  • Multifocal Electroretinogram (MFERG)(up to 12 months)

研究者

发起方
Southwest Hospital, China
申办方类型
Other
责任方
Principal Investigator
主要研究者

ZhengQin Yin

Professor

Southwest Hospital, China

研究点 (1)

Loading locations...

相似试验

Clinical Study of Subretinal Transplantation of... | 临床试验